Main ContentREVERSE Study
Study title
A Phase 3, double-blind, randomized, placebo-controlled, multicenter study to evaluate the efficacy and safety of obeticholic acid in subjects with compensated cirrhosis due to non-alcoholic steatohepatitis
- Principal Investigator: Dr. Thomas Amankonah
Purpose
The study is looking at the use of an experimental drug to see if it improves liver fibrosis and associated symptoms in adults with compensated cirrhosis due to non-alcoholic steatohepatitis (NASH).
Who can participate
Those eligible to participate in this study include:
- Adults ages 18 and older with compensated cirrhosis due to non-alcoholic steatohepatitis (NASH)
For more information